[
    [
        {
            "time": "2023-10-01",
            "original_text": "Big Drug Stocks Have Rallied. Why an Analyst Says They Have More Room to Run.",
            "features": {
                "keywords": [
                    "Drug Stocks",
                    "Rallied",
                    "Analyst",
                    "More Room"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Big Drug Stocks Have Rallied. Why an Analyst Says They Have More Room to Run.",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "10 Best Dividend Stocks to Buy According to Billionaire Mario Gabelli",
            "features": {
                "keywords": [
                    "Dividend Stocks",
                    "Buy",
                    "Billionaire",
                    "Mario Gabelli"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividends"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "10 Best Dividend Stocks to Buy According to Billionaire Mario Gabelli",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI速) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Risankizumab",
                    "SKYRIZI",
                    "Clinical Remission",
                    "Crohn's Disease"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI速) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ速 (upadacitinib) in Atopic Dermatitis",
            "features": {
                "keywords": [
                    "The Lancet",
                    "RINVOQ",
                    "Phase 3",
                    "Atopic Dermatitis"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ速 (upadacitinib) in Atopic Dermatitis",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "JNJ's Stelara Fails to Beat AbbVie's Humira In Crohn's Disease Patients",
            "features": {
                "keywords": [
                    "JNJ",
                    "Stelara",
                    "AbbVie",
                    "Humira",
                    "Crohn's Disease"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "JNJ's Stelara Fails to Beat AbbVie's Humira In Crohn's Disease Patients",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]